Peptide Probe Fluorescent Detection of Amyloid Beta Oligomers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for reliable methods to detect Aβ oligomers in biological samples, as they provide insight into the risk, presence, progression, severity, and prognosis of Alzheimer's disease and the efficacy of therapeutic agents.
Innovation Solution
The method involves preparing a test sample with a biological sample and a peptide probe that preferentially binds to Aβ oligomers, labeled with a fluorescent label. This sample is then subjected to flow cytometry to detect the fluorescent signal of the complexes formed with Aβ oligomers, correlating the signal with the presence and amount of Aβ oligomers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for Aβ oligomers, then the detection process is simple, but the detection precision and reliability are insufficient
Solution Approach 1:
The patent introduces a peptide probe as an intermediary molecule that specifically binds to Aβ oligomers. This probe acts as a mediator between the target analyte (Aβ oligomers) and the detection system (flow cytometer), enabling precise detection through fluorescent labeling. The peptide probe specifically recognizes and binds to Aβ oligomers, forming detectable complexes that allow for accurate quantification while maintaining operational simplicity.
2Reliability
If Aβ oligomers are not detected, then the detection method is straightforward, but the ability to assess disease risk and progression is lost
Solution Approach 1:
The patent employs fluorescent labeling of the peptide probe, which produces a detectable fluorescent signal when bound to Aβ oligomers. This optical signal change enables reliable detection and quantification of Aβ oligomers in biological samples. The fluorescent signal intensity correlates with the amount of Aβ oligomers present, providing a reliable measure for assessing Alzheimer's disease risk, presence, progression, severity, and prognosis.
3Measurement precision
If specific peptide probes are used to bind Aβ oligomers, then the detection specificity is improved, but the sample preparation complexity increases
Solution Approach 1:
The peptide probe is designed to autonomously recognize and bind to Aβ oligomers in the biological sample without requiring complex sample preparation or purification steps. The probe self-assembles with the target analyte through specific molecular recognition, forming detectable complexes directly in the sample matrix. This self-service binding mechanism maintains high detection specificity while minimizing sample preparation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively detects Aβ oligomers in biological samples, allowing for the assessment of Alzheimer's disease risk, progression, and therapeutic efficacy by quantifying the amount of Aβ oligomers present.
Implementation Method 1
the peptide probe is labeled with a fluorescent label capable of emitting a fluorescent signal
Implementation Method 2
the peptide probe preferentially binds to Aβ oligomers and is labeled with a fluorescent label... the peptide probe forms complexes with any Aβ oligomer present in the biological sample
Data Source
Figure 1
Figure 1
Figure 1
AI summary
Methods of detecting Aβ oligomers, such as may be present in a biological sample are described. The methods include detection using flow cytometry, detection using synthetic Aβ oligomers and/or in vitro methods detecting Aβ oligomers associated with cells.